Freudenberg Introduces HelixTC Sanitary Ends for Bioprocessing Applications

Expanded capabilities include overmolded components for biopharmaceutical fluid transfer assemblies

Freudenberg Medical, a manufacturer of medical and pharmaceutical devices, systems, components, and tubing, has introduced HelixTC™ overmolded sanitary ends in silicone for use in bioprocessing and single-use fluid transfer applications.

HelixTC is an alternative to standard barbed TC connections and is based on Freudenberg’s PharmaFocus® Premium product line of platinum-cured silicone tubing.

Available in standard or mini molded TC styles up to 1½ inch or 50mm OD and custom sizes or custom assemblies are available to order. The product comes with either stainless steel or polysulfone back-up cups.

“We are proud to launch our new HelixTC™ product line, which combines our extensive capabilities and expertise in tubing extrusion and injection molding,” states Rudi Gall, General Manager & Director Corporate Marketing at Freudenberg Medical. “With HelixTC™, which is designed around our well-proven silicone-based PharmaFocus® Premium tubing line, we extend our overall offerings to our pharmaceutical and biopharmaceutical customers. We are a true one-stop shop, making development and sourcing of products easier and faster for our customers. HelixTC™ is another example of how we aim to make life easier for our customers.”

Explore Freudenberg’s full line of biopharmaceutical products.

Visit us at these upcoming industry events – ISPE Boston Product Show, BioProcess International Conference & Exhibition, and CPhI India.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.